Pharma Wholesale and Distribution Market Forecasts 2020-2030

1. Report Overview 1.1 Global Pharma Wholesale and Distribution Industry and Market Overview 1.2 Benefits of This Report 1.3 How This Report Delivers 1.4 Questions Answered by This Analytical Report 1.5 Who is This Report For? 1.6 Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain 2. Introduction to Pharma Wholesale and Distribution 2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry 2.1.1 Full-Line Wholesalers (FLWs) 2.1.2 Short-Line Wholesalers (SLWs) 2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers 2.2.1 Secondary Wholesalers 2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent 2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits 2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain 2.2.5 Pharmacy Benefit Managers 2.3 Generative Revenue and Profit 2.3.1 Forward Buying to Avoid Price Increases 2.3.2 Fee-for-Service: A Clear Pricing Structure 2.3.2.1 Inventory Management Agreements 2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases 2.3.4 Reimbursement and Wholesalers 2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments 2.3.6 Parallel Trade: Different Attitudes in Europe and the US 3. The World Pharmaceutical Wholesale and Distribution Market: 2020-2030 3.1 The World Pharmaceutical Wholesale and Distribution Market, Restricted by Government Price Reductions and Generic Substitution 3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2018-2030 3.3 Branded and Generic Drugs: Revenue vs. Profit, 2018-2030 3.3.1 Branded and Generic Drugs: Revenue Generation, 2017 3.3.2 Branded Drugs: Revenue Forecast, 2018-2030 3.3.3 Generic Drugs: Revenue Forecast, 2018-2030 4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2020-2030 4.1 The Leading National Markets: the US Dominates in 2018 4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market? 4.3 The US Pharma Wholesale and Distribution Market 4.3.1 Specialty Pharmacies Hinders the Growth of Wholesaler's Business 4.3.2 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry 4.3.3 Legislation to Prevent Counterfeit Drugs Can Differ Between States 4.3.4 An Increase in Fee-For-Service Activity 4.3.5 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2018-2030 4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets 4.4.1 The Difference Between the US and European Markets 4.4.2 State-Funded Healthcare and Reimbursement 4.4.3 EU5: Market Forecast, 2018-2030 4.4.4 Germany: Pharma Wholesale and Distribution Market 4.4.4.1 Healthcare Reform 4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law 4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.4.5 France: Pharma Wholesale and Distribution Market 4.4.5.1 France: Social Security Finance Bill 2015 4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.4.6 Italy: Pharma Wholesale and Distribution Market 4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.4.7 Spain: Pharma Wholesale and Distribution Market 4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.4.8 UK: Pharma Wholesale and Distribution Market 4.4.8.1 Price Cuts in the UK 4.4.8.2 Surge in Price of Generic Drugs 4.4.8.3 UK: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.5 Japan: Pharma Wholesale and Distribution Market 4.5.1 Drug Pricing and Performing Fees in Japan 4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.6 China: Pharma Wholesale and Distribution Market 4.6.1 China: Leading Pharma Wholesale and Distribution Companies 4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.7 Brazil: Pharma and Wholesale Distribution Market 4.7.1 Drug Price Controls in Brazil 4.7.2 Brazil: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.8 India: Pharma Wholesale and Distribution Market 4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.9 Russia: Pharma Wholesale and Distribution Market, 2016 4.9.1 Drug Pricing Controls in Russia 4.9.2 Market Trends in Russia 4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2018-2030 4.10 Conclusion 5. Leading Pharma Wholesalers and Distributors: 5.1 The Leading Pharma Wholesalers and Distribution Companies, 2018 5.2 Leading Pharma Wholesale and Distribution Companies, Drivers and Restraints 5.3 McKesson Corporation 5.3.1 McKesson: Sales and Recent Performance Analysis, 2019 5.3.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses 5.3.3 McKesson: Recent Developments, 2016-2019 5.3.3.1 Acquisition of Medical Specialties Distributors 5.3.3.2 Acquisition of GMD Distribution, Inc. 5.3.3.3 Partnership with Walmart 5.3.3.4 Acquisition of UDG's Irish Pharmaceutical Distribution Business 5.4 Cardinal Health 5.4.1 Cardinal Health: Sales and Recent Performance Analysis, 2018 5.4.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth? 5.4.3 Cardinal Health: Recent Developments, 2016-2019 5.4.3.1 Closing of pharmaceutical packaging center and a distribution warehouse 5.4.3.2 Divestiture of Cardinal Health's China Business 5.5 AmerisourceBergen 5.5.1 AmerisourceBergen: Sales and Recent Performance Analysis, 2018 5.5.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth? 5.5.3 AmerisourceBergen: Recent Developments, 2016-2019 5.5.3.1 Closing of California Distribution Center 5.5.3.2 Joint Venture with Profarma Distribuidora 5.5.3.3 Acquisition of H.D.Smith 5.6 Walgreens Boots Alliance 5.6.1 Walgreens Boots Alliance, Sales and Recent Performance Analysis, 2018 5.6.2 Walgreen Boots Alliance: Recent Developments, 2016-2019 5.7 Medipal Holdings Corporation 5.7.1 Medipal: Sales and Recent Performance Analysis, 2018 5.7.2 Future Strategies of Medipal Holdings Corporation: Revised Business Portfolio with Diverse Sources of Earnings 5.7.3 Medipal: Recent Developments, 2016-2019 5.8 Phoenix Group 5.8.1 The PHOENIX Group: Sales and Recent Performance Analysis, 2018 5.8.2 Future Strategies of the PHOENIX Group: Selective Acquisition 5.8.3 Phoenix Group: Recent Developments, 2016-2019 5.8.3.1 Acquisition of Farmexim S.A. and the Help Net Farma S.A. 5.9 Sinopharm Group Co. Ltd. 5.9.1 Sinopharm, Sales and Recent Performance Analysis, 2018 5.9.2 Future Strategies of Sinopharm: Provide Comprehensive Services and Wider Business Coverage 5.9.3 Sinopharm: Recent Developments, 2016-2019 5.10 Alfresa Holdings Corporation 5.10.1 Alfresa, Sales and Recent Performance Analysis, 2018 5.10.2 Alfresa: Recent Developments, 2016-2019 5.11 Suzuken Co., Ltd 5.11.1 Suzuken Co. Ltd, Sales and Recent Performance Analysis, 2018 5.11.2 Future Strategies of Suzuken CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field 5.11.3 Suzuken: Recent Developments, 2016-2019 5.11.3.1 Collaboration with Toho Holdings Co., Ltd. 5.11.3.2 Collaboration with World Courier 5.11.3.3 Agreement with AmerisourceBergen 5.12 Shanghai Fosun Pharmaceuticals Co. Ltd. 5.12.1 Shanghai Fosun Pharmaceuticals, Sales and Recent Performance Analysis, 2018 5.12.2 Future Strategies of Shanghai Fosun Pharma: Expansion of Three Leading Regions in China 5.12.3 Shanghai Fosun Pharmaceuticals: Recent Developments, 2016-2019 5.12.3.1 Acquisition of Cardinal Health's China Business 5.12.3.2 Acquisition of Tridem Pharma 5.13 CR Pharmaceuticals 5.13.1 CR Pharmaceuticals: Sales and Recent Performance Analysis, 2018 5.13.2 CR Pharmaceuticals: Recent Developments 5.13.2.1 Strategic cooperation agreement with Novartis 5.13.2.2 Collaboration with China Merchants Bank and Shenzhen Qianhai WeBank 5.14 Morris and Dickson 5.14.1 Morris and Dickson: Sales and Recent Performance Analysis, 2018 5.14.2 Morris and Dickson: Recent Developments 5.14.3 Smith Drug Company 5.14.4 Smith Drug Company: Sales and Recent Performance Analysis, 2018 5.14.5 Smith Drug Company: Recent Developments 5.15 CuraScript SD 5.15.1 CuraScript SD: Sales and Recent Performance Analysis, 2018 5.15.2 CuraScript SD: Recent Developments 5.16 Mutual Drug Company 5.16.1 Mutual Drug Company: Sales and Recent Performance Analysis, 2018 5.16.2 Mutual Drug Company: Recent Developments 6. Qualitative Analysis of The Pharma Wholesale and Distribution Market 6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market 6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry? 6.1.2 Wholesalers Do More than Deliver Drugs 6.1.2.1 Pre-Wholesaling: More Prevalent in Europe 6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market 6.1.3 Large Companies Dominate the Market 6.1.4 Despite High Revenues, Profit Margins Are Low 6.1.5 Government-Induced Drug Price Pressures Restrict Profits 6.1.6 The Problem of Counterfeit Drugs 6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2018-2030 6.2.1 The Demand for Pharmaceuticals is Increasing 6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth 6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue but Drive Profit Generation 6.2.4 The Promotion of Drug Therapy in the US 6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies 6.2.6 Increased Adoption of the DTP Distribution Model 6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold 6.2.6.2 DTP in the UK Since 1991 6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model 6.2.6.4 Further Expansion of the DTP Model 6.2.7 The Threat of Healthcare Budget Cuts 6.2.7.1 Healthcare Budget Cuts in Germany 6.2.7.2 Healthcare Budget Cuts in France 6.2.7.3 Healthcare Budget Cuts in Italy 6.2.7.4 Healthcare Budget Cuts in Spain 6.2.7.5 Healthcare Budget Cuts in the UK 6.2.8 Do Large Pharmacy Chains Pose a Threat? 6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme 6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains 6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry? 6.2.10 The Threat of Industry Consolidation 6.3 Social, Technological, Economic and Political Factors Influencing the Market, 2018-2030 (STEP Analysis) 6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU 6.3.2 Political Factor: Combating Counterfeit Medicines 6.3.2.1 The US and E-Pedigree: Becoming Law in California 6.3.2.2 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge 6.3.2.3 Serialisation for Wholesalers: Opportunity or a Challenge? 7. Conclusions 7.1 Specialty Drug Products to Drive Growth in the Pharma Wholesale and Distribution Market 7.2 The Leading National Pharma Wholesale and Distribution Markets 7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry 7.4 Trends in the Pharma Wholesale and Distribution Industry 7.4.1 Generics Will Threaten Revenue Growth 7.4.2 Manufacturers Will Deliver More Drugs Directly 7.4.3 There Will Be Greater Demand for Specialty Medicines 7.4.4 Consolidation Will Drive Growth 7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form List of Tables TABLE 2.1 USE OF DTP MODEL IN THE UK, 2007-2012 TABLE 3.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), AGR (%), CAGR (%), 2018-2030 TABLE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: BRANDED DRUGS, GENERIC DRUGS AND OTHERS, REVENUE ($BN) FORECASTS, AGR (%), CAGR (%) AND MARKET SHARES (%), 2018-2030 TABLE 3.3 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030 TABLE 3.4 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030 TABLE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: REVENUES ($BN) AND MARKET SHARE (%), 2018 Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2018-2030 TABLE 4.3 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.4 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.5 PRICE CONTROLS IN EUROPE, 2016 TABLE 4.6 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.7 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.8 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.9 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.10 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.11 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.12 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.13 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.14 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.15 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.16 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.17 PERCENTAGE OF THE POPULATION AGES 60+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030 TABLE 4.18 JAPANESE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRUG PRICE REVISION GROWTH (%), 2006-2016 TABLE 4.19 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.20 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.21 CHINESE PHARMA WHOLESALE & DISTRIBUTION: REVENUE ($BN) AND MARKET SHARES (%) OF LEADING COMPANIES, 2018 TABLE 4.22 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.23 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.24 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.25 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.26 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.27 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.28 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030 TABLE 4.29 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 TABLE 5.1 LEADING COMPANIES IN THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: REVENUES ($BN) AND MARKET SHARES (%), 2018 TABLE 5.2 MCKESSON: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2015-2019 TABLE 5.3 ACQUISITIONS BY MCKESSON, 2007-2019 TABLE 5.4 CARDINAL HEALTH: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.5 SELECTED ACQUISITIONS BY CARDINAL HEALTH AND THEIR LINE OF BUSINESS, 2007-2019 TABLE 5.6 AMERISOURCEBERGEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.7 ACQUISITIONS BY AMERISOURCEBERGEN AND THEIR LINE OF BUSINESS, 2007-2019 TABLE 5.8 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.9 MEDIPAL: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.10 PHOENIX GROUP: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.11 SINOPHARM: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.12 ALFRESA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.13 SUZUKEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.14 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 5.15 CR PHARMACEUTICALS: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018 TABLE 6.1 THE PHARMACEUTICAL W&D MARKET: STRENGTHS AND WEAKNESSES TABLE 6.2 THE PHARMACEUTICAL W&D MARKET: OPPORTUNITIES AND THREATS, 2019-2030 TABLE 6.3 STRENGTHS AND WEAKNESSES OF THE DTP DISTRIBUTION MODEL TABLE 6.4 ITR RATINGS AND CORRESPONDING REIMBURSEMENT RATES TABLE 6.5 SOCIAL, TECHNOLOGICAL, ECONOMIC AND POLITICAL FACTORS INFLUENCING THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET (STEP ANALYSIS List of Figures FIGURE 2.1 ROUTES OF DRUG DISTRIBUTION FIGURE 3.1 THE GLOBAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), 2018-2030 FIGURE 3.3 BRANDED DRUGS, GENERIC DRUGS, AND OTHERS: MARKET SHARES (%), 2018 FIGURE 3.4 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN) BY CATEGORY, 2018-2030 FIGURE 3.5 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2025 FIGURE 3.6 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2030 FIGURE 3.7 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS, GENERIC DRUGS AND OTHERS: REVENUE FORECASTS ($BN), 2018-2030 FIGURE 3.8 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 3.9 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2018 FIGURE 4.2 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2025 FIGURE 4.3 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2030 FIGURE 4.4 US PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: SHARE (%), 2018 FIGURE 4.5 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.6 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.7 US PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.8 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2018 FIGURE 4.9 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2025 FIGURE 4.10 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2030 FIGURE 4.11 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, 2018-2030 FIGURE 4.12 EU PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.13 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.14 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.15 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.16 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.17 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.18 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.19 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.20 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.21 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017 FIGURE 4.22 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.23 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.24 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017 FIGURE 4.25 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN), 2018-2030 FIGURE 4.26 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.27 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.28 PERCENTAGE OF THE POPULATION AGES 65+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030 FIGURE 4.29 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.30 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.31 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.32 CHINESE PHARMA WHOLESALE & DISTRIBUTION: MARKET SHARES (%), 2018 FIGURE 4.33 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.34 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.35 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.36 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.37 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.38 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.39 PHARMA WHOLESALE & DISTRIBUTION MODEL IN INDIA FIGURE 4.40 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.41 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.42 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 4.43 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.44 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030 FIGURE 4.45 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS FIGURE 5.1 LEADING PHARMACEUTICAL WHOLESALE AND DISTRIBUTION COMPANIES: MARKET SHARES (%), 2018 FIGURE 5.2 LEADING PHARMACEUTICAL W&D COMPANIES: DRIVERS AND RESTRAINTS FIGURE 5.3 MCKESSON: HISTORICAL REVENUE ($BN), 2015-2019 FIGURE 5.4 MCKESSON: DRIVERS AND RESTRAINTS FIGURE 5.6 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.7 CARDINAL HEALTH: DRIVERS AND RESTRAINTS FIGURE 5.8 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.9 AMERISOURCEBERGEN: DRIVERS AND RESTRAINTS FIGURE 5.10 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.11 WALGREEN BOOTS ALLIANCE: DRIVERS AND RESTRAINTS FIGURE 5.12 MEDIPAL: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.13 MEDIPAL HOLDINGS: DRIVERS AND RESTRAINTS FIGURE 5.14 PHOENIX GROUP: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.15 PHOENIX GROUP DRIVERS AND RESTRAINTS FIGURE 5.16 SINOPHARM: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.17 SINOPHARM GROUP: DRIVERS AND RESTRAINTS FIGURE 5.18 ALFRESA: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.19 ALFRESA: DRIVERS AND RESTRAINTS FIGURE 5.20 SUZUKEN: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.21 SUZUKEN: DRIVERS AND RESTRAINTS FIGURE 5.22 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 5.23 SHANGHAI FOSUN PHARMACEUTICALS: DRIVERS AND RESTRAINTS FIGURE 5.24 CR PHARMACEUTICALS: HISTORICAL REVENUE ($BN), 2014-2018 FIGURE 6.1 COMPARISON OF THE WHOLESALE AND DTP ROUTES OF DISTRIBUTION FIGURE 7.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: GLOBAL MARKET FORECASTS ($BN) BY SUBMARKET, 2018-2030 FIGURE 7.2 LEADING NATIONAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKETS: REVENUE PROJECTIONS ($BN), 2018, 2025 AND 2030